Boston Scientific to Discuss Q2 2025 Financial Results and Business Highlights

MARLBOROUGH, Mass. – July 1, 2025 – Boston Scientific Corporation (NYSE: BSX) today announced it will host a conference call and webcast to discuss its financial results and business highlights for the second quarter ended June 30, 2025. The event is scheduled for Wednesday, July 23, 2025, at 8:00 a.m. Eastern Time.

This upcoming conference call is a routine but crucial event for investors, analysts, and stakeholders to gain insights into Boston Scientific's performance over the past quarter. The medical technology giant, known for its innovative solutions across various therapeutic areas including cardiovascular, urology, and neuromodulation, typically provides a detailed breakdown of its revenue streams, profitability, and operational achievements during these calls.

What to Expect from the Q2 2025 Earnings Call

Investors will be keenly watching for several key metrics and updates:

• Revenue Performance: Analysts will scrutinize total revenue figures, segment-specific sales (e.g., Cardiovascular, MedSurg, Rhythm and Neuro), and geographic performance to assess growth drivers and potential headwinds.
• Profitability Margins: Gross margins, operating margins, and net income will provide a clear picture of the company's efficiency and cost management. Any shifts in these figures could signal changes in product mix or operational strategies.
• Earnings Per Share (EPS): The reported EPS, both GAAP and non-GAAP, will be a primary focus, compared against analyst consensus estimates. Surprises, positive or negative, often lead to significant stock price movements.
• Product Pipeline and Approvals: Updates on ongoing clinical trials, new product launches, and regulatory approvals (e.g., FDA, CE Mark) are vital for understanding future growth prospects. Boston Scientific has a robust pipeline, and any advancements here could be a significant catalyst.
• Guidance for Q3 and Full Year 2025: Management's outlook for the upcoming quarter and the remainder of the fiscal year is perhaps the most impactful element. Revised guidance, whether upward or downward, provides critical foresight into the company's expected trajectory and market conditions.
• Strategic Initiatives: Discussions around mergers and acquisitions, divestitures, or strategic partnerships will offer insights into the company's long-term growth strategy and market positioning.

Market Context and Investment Implications

The medical technology sector has shown resilience amidst broader economic uncertainties, driven by an aging global population, increasing demand for advanced healthcare solutions, and continuous innovation. Boston Scientific operates in a competitive yet growing market, making its ability to innovate and execute crucial.

For BSX shareholders, the Q2 earnings call is an opportunity to validate investment theses. Strong results, particularly in key growth areas like structural heart or peripheral interventions, could reinforce confidence. Conversely, any signs of slowing growth, margin pressure, or pipeline setbacks might prompt re-evaluation.

Potential catalysts for BSX include successful product launches, positive clinical trial data, and strategic acquisitions that expand its market reach or technological capabilities. Risks include increased competition, regulatory hurdles, and potential supply chain disruptions.

How to Access the Webcast

Boston Scientific will provide access to the live webcast and accompanying slides through the 'Investors' section of its corporate website at www.bostonscientific.com/investors. A replay of the webcast will also be available on the same section of the website for an extended period following the call. This accessibility ensures that all interested parties can review the information at their convenience.

Investors are encouraged to review the company's latest financial reports and SEC filings, including its Form 10-K and 10-Q, for a comprehensive understanding of its financial health and operational risks ahead of the call. The Q2 2025 results will offer a fresh perspective on Boston Scientific's trajectory in a dynamic healthcare landscape.